Implant for Walking After Stroke

Stroke Clinical Trial

Official title:

Customizable Cooperative Multi-joint Control to Enhance Walking Mobility After Stroke

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05740540
• Other study ID #: StudyID00000125
• Status: Recruiting
• Phase: N/A
• Start date: May 16, 2023
• Est. completion date: March 31, 2027

Study information

• Verified date: June 2023
• Source: MetroHealth Medical Center
• Contact: Lisa Lombardo, MPT
• Phone: 216-791-3800
• Email: lisa.lombardo2[@]va.gov
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a device study that will evaluate the effect of an implanted stimulator on improving walking in stroke survivors. There are two phases in the study: 1) Screening - this phase determines if the individual is a good candidate to receive an implanted system, 2) Implantation, controller development, and evaluation - this phase includes installing the device and setting the individual up for home use, creating advanced controllers for walking and evaluating the effect of the device over several months.

Description:

The purpose of this study is to evaluate the effects of neural stimulation for improving walking after stroke. Participants will undergo surgery to implant a stimulator and electrodes to activate muscles used during walking. The device delivers electrical pulses to the nerves causing the muscles to contract to perform functional movements. The system coordinates assistance based on external sensors. After receiving the implanted device, participants undergo training to use the device to assist walking. Evaluations are completed prior to surgery as well after training and at later follow up sessions.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 6
• Est. completion date: March 31, 2027
• Est. primary completion date: March 31, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 75 Years

Eligibility

Inclusion Criteria:

• At least 6-months post stroke
• Age 21 to 75 years old
• Able to ambulate, but does not require the assistance of more than one person
• Walk slower than 0.8m/s during a 10m walk test
• Lower extremity Fugl-Meyer Motor Assessment (FMA) <= 20
• Reduced peak hip, knee and/or ankle range of motion during stance or swing phases
• Modified Ashworth Scale (MAS) <= 2 at the above joints during passive flexion and extension
• Innervated and excitable lower extremity and trunk musculature
• Appropriate body habitus (height and weight within acceptable limits as determined by study physician)
• Adequate social support and stability
• Willingness to comply with follow-up procedures
• Neurologically stable as determined by a physician

Exclusion Criteria:

• Non-English speaking
• Significant range of motion limitations (lacking hip extension, etc.)
• History of spontaneous fractures or other evidence of excessively low bone density
• Acute orthopedic problems (severe scoliosis, joint dislocations, etc.)
• Medical complications (cardiac abnormalities, skin breakdowns, uncontrolled seizures, immunological/pulmonary/renal/circulatory compromise, additional neurologic conditions etc.)
• Cardiovascular or pulmonary disease
• Uncontrolled diabetes or hypertension
• Presence of a demand pacemaker or cardiac defibrillator
• Pregnancy
• Complications of stroke that result in an increased risk of falls (apraxia, uncompensated hemineglect, hemianopsia etc.)
• Significant history of repeated falls
• Severely impaired cognition and communication
• Any other medical or psychological condition that would be a contraindication

Related Conditions & MeSH terms

• Gait Disorders, Neurologic
• Gait, Hemiplegic
• Hemiplegia
• Stroke

Intervention

Device:
• IRS-8
Implanted Receiver Stimulator (IRS) delivering 8 channels of stimulation. Appropriate for muscle-based (intramuscular or epimysial) electrodes only
• IST 12 & IST 16
Implantable Stimulator Telemeter (IST) that provides 12 independent channels of stimulation with the option of 2 channels of bipolar myoelectric signal recording, or 16 independent stimulus channels. Suitable for muscle-based or nerve cuff electrodes such as the CWRU Spiral, Flat Interface Nerve Electrode (FINE) or Composite-Flat Interface Nerve Electrode (C-FINE).

Locations

Country	Name	City	State
United States	Louis Stokes Cleveland Veterans Affairs Medical Center	Cleveland	Ohio
United States	MetroHealth Medical Center	Cleveland	Ohio

Sponsors (4)

Lead Sponsor	Collaborator
MetroHealth Medical Center	Case Western Reserve University, Cleveland State University, Louis Stokes VA Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in Gait speed	The 10mWT is used to assess walking speed in meters/second (m/s) over a short distance.; Gait speed is how we're evaluating whether the advanced controller works better than a simple generic triggering approach.	baseline, ~18 weeks post implant, ~44 week post implant
Secondary	Difference in Usability Rating Scale (URS)	participants will rate the task on a seven-point scale from "very easy" (3) to "very difficult" (-3). Difficulty will be assessed after the 10 m walk test	baseline, ~18 weeks post implant, ~44-week post implant